Tanshinone in Polycystic Ovary Syndrome
Tanshinone in Polycystic Ovary Syndrome
Tanshinone was originally isolated from dried roots of Salvia miltiorrhiza bunge. In Chinese
 medicine, this herb has been widely prescribed for several pathologies, including diabetes,
 acne, cardiovascular disease.It has been demonstrated that the therapeutic benefit of
 cryptotanshinone on prenatally androgenized rats may be mediated by its dual regulation of
 key molecules during both insulin signaling and androgen synthesis.The purpose of this study
 is to determine whether tanshinone may prove effective in eradicating Polycystic Ovary
 Syndrome (PCOS) symptomatology.
Inclusion Criteria:

 -  Presence of PCOS diagnosed based on the Androgen Excess Society criteria. All subjects
 must have hyperandrogenism (hirsutism and/or hyperandrogenemia), ovarian dysfunction
 (oligoanovulation and/or polycystic ovaries), and exclusion of other androgen excess
 related disorders. Oligomenorrhea is defined as an intermenstrual interval >35 days or
 <8 menstrual bleedings in the past year. Amenorrhea is defined as an intermenstrual
 interval >90 days. Clinical hyperandrogenism is defined as a Ferriman-Gallwey (FG)
 score ≥5

 -  Age of women from 18 to 35 years；

 -  No desire of children within 6 month and use condoms for contraception.

 Exclusion Criteria:

 -  Use of hormonal drugs or other medications, which can affect the results of the study
 especially Chinese herbal prescriptions in the past 12 weeks；

 -  Patients with other androgen excess endocrine disorders including 21-hydroxylase
 deficiency, hyperprolactinemia, Cushing syndrome, severe insulin resistance, thyroid
 dysfunction；

 -  Patients with history of sever cardiac , pulmonary, hepatic, renal, neurologic disease
 or mental illness；

 -  Pregnancy or lactation.